ArticleScientific reports2025
IGF-1R promotes pain-like behavior in rats with myofascial pain syndrome via the PI3K/AKT pathway.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Downregulation of ClC-3 chloride channels in dorsal root ganglia neurons contributes to bone metastasis-induced pain.The Journal of biological chemistry · 2026Article
- Development and internal validation of a therapeutic effect predictive model for myofascial pain syndrome.Frontiers in neurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Myofascial pain syndrome (MPS) is a common chronic pain condition characterized primarily by the presence of myofascial trigger points (MTrPs). While the insulin-like growth factor-1 receptor (IGF-1R) is known to be upregulated in injured muscles and implicated in orofacial neuropathic pain, its role in the peripheral mechanisms underlying MTrPs remains poorly understood. In this study, we aimed to investigate the expression of IGF-1R in MTrPs and explore the molecular mechanisms by which IGF-1R activation induces pain-like behavior in a rat model of MTrPs. We used Sprague-Dawley rats to assess IGF-1R signaling, measuring pain-like behaviors with the Randall-Selitto test. Muscle tissue morphology was examined using hematoxylin and eosin (HE) staining, while IGF-1R-related proteins were quantified through immunohistochemistry (IHC) and Western blot (WB) analysis. Our results showed that IGF-1R expression is significantly elevated in the muscle tissue of rats with MTrPs, with this upregulation correlating positively with the hyperalgesia. Furthermore, activation of IGF-1R was found to induce pain-like behavior via the phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) pathway. Notably, inhibition of PI3K/AKT reversed the pain-like behaviors triggered by IGF-1R activation. These findings suggest that the increased expression of IGF-1R and subsequent activation of the PI3K/AKT/mTOR pathway may contribute to heightened nociception in MTrPs, offering new insights into the molecular mechanisms underlying MPS and potential targets for therapeutic intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.